Heron Therapeutics (HRTX) Q4 2024 earnings summary

Executive summary

• Achieved profitability for both Q4 and full year 2024, with Q4 GAAP net income of $3.6 million and full-year net revenue of $144.2 million, marking a significant turnaround.

• Expanded ZYNRELEF's label, doubled approved procedures, secured NOPAIN Act inclusion for broader reimbursement, and launched the Vial Access Needle (VAN) in December 2024.

• Won key patent litigation, upholding CINVANTI patents through 2035 and reducing legal uncertainty.

• Announced partnership with CrossLink to expand ZYNRELEF promotion, with 800 reps driving higher account growth rates.

Financial highlights

• Q4 2024 net income was $3.6–$3.7 million, reversing prior losses; Q4 net revenue was $40.8 million, up 19.1% year-over-year.

• Full year 2024 net revenues reached $144.2 million, up 14% year-over-year; gross profit was $105.6 million.

• Adjusted EBITDA for 2024 was $8.6 million, a substantial improvement from a loss in 2023.

• Gross margin improved from 49% in 2023 to approximately 73% in 2024.

• Ended 2024 with $59.3 million in cash and short-term investments.

Outlook and guidance

• 2025 product net revenue guidance: $153–$163 million; adjusted EBITDA guidance: $0–$8 million.

• Expect continued growth in ZYNRELEF and APONVIE, with ZYNRELEF inflection anticipated mid-2025 and continued CMS separate payment through at least 2027.

• Oncology franchise (CINVANTI, SUSTOL) expected to see unit growth but potential ASP pressure due to competition.

• Partnership with CrossLink Network, LLC to expand ZYNRELEF promotion in orthopedic surgery.